Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-04 08:53 am Sale | 2021-12-31 | 13G | Verve Therapeutics, Inc. VERV | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 1,871,679 3.890% | -623,892 (-25.00%) | Filing |
| 2021-06-28 08:50 am Purchase | 2021-06-17 | 13G | Verve Therapeutics, Inc. VERV | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 2,495,571 5.180% | 2,495,571 (New Position) | Filing |